Portal de Periódicos da CAPES

Palivizumab prophylaxis of respiratory syncytial virus disease in 2000–2001: Results from the palivizumab outcomes registry

2003; Wiley; Volume: 35; Issue: 6 Linguagem: Inglês

10.1002/ppul.10288

8755-6863

Curt Parnes, Judith Guillermin, Rolf Habersang, Peggy Nicholes, Vijay Chawla, Tammy Kelly, Judith Fishbein, Patty McRae, Mary Goessler, Antoinette Gatti, John A Calcagno, Cheryl Eki, Kristen A Harris, Joseph L. Joyave, Kathy McFarland, Paul Protter, Mary C. Sullivan, A. Stanford, Nancy Lovett, Marisol Ortiz, S. Rojas Rojas, S Cyrus, Janell Cyrus, Stuart A. Cohen, Debbie Buchin, Linda Riordan, Monica Zuniga, Rupa D. Shah, Carmen Minard, Arden Quintin, Glenda Douglas, John van Houten, Sharyn Freutner, Stephen A. Chartrand, Patsy Nowatzke, José R. Romero, Torunn T. Rhodes, Michelle Benoit, Emmanuel B. Walter, Leslie R. Walker, Laurie DeBonnett, Mia Cross, Teresa A. Free, Sharman Martin, Karen Shank, B. L. da S. Guedes, Lee Ann Atkinson, George J Halpin, Kathy Rouse, Ivan Hand, Donna Geiss, James R. Marshall, Lois Burleson, Jim Boland, Kelsey Seybold, Vicki Hunter, Susan Unfer, Jackie Schmucker, Margaret Gley, Michael Marcus, Patricia A. Thompson, Paulino Milla, Connie Young, Robert Zanni, Virginia Zinno, Alexandra Fetter-Zarzeka, Amanda Busey, Modupe A Sokunbi, Sherrie Airington, Nancy Richard, Vellore Muraligopal, Stephanie Lewis, Fred Weber, Beverly P. Giordano, D. Linehan, Jane Roach, Randle Davis, Andrew A Rzepka, Teri Booth, David Smeltzer, Jeanne Walsh, Emilio Arispe, Rhonda Rowley, Christopher Bolling, Tanya Botts, Kateri Haskett, Deana Raby, Evelyn Batiz, Andrew Gelfand, Lynn E. Farrell, Stephen Butler, Linda Colby, Peter Z. Schochet, Julie Bentler, David Hirsch, Lisa Wilkinson, A Aaronson, Eleanora Bennett, Julie Wingate, Dawn Quinn, Katherine Komendowski, Marcia Deckard, Michael Frogel, Cliff Nerwen, Steven Copenhaver, M. Renée Prater, Jacob Wolsztein, Kristine Mackey, Marshall Benbow, Marisela Naranjo, S. D. Hensley, Cindy Hayes, Hossein Sadeghi, S. Lawson, Mark R. McCall, K A Combs, Joel Ledbetter, Karen Sarnosky, Cathy Swafford, Michael E. Speer, Wendy J Barton, Jonathan W. Mink, Dianne Lemm, Mark L. Hudak, Elizabeth Case, Judith L. Rowen, Sandra Fuentes, Carly Pane, Leslie Richardson, C Chavarria, Deanne Cassino, Kourosh Ghaffari, Carol Carroll, Haesoon Lee, Lydia Guclu, Christopher Johnson, V. Blum, Marnie L. Boron, Mark Sorrentino, Robert L. Hirsch, Paul C. Van Veldhuisen, Carol A. Smith,

Pneumonia and Respiratory Infections

Abstract The objective of the Registry was to characterize the population of infants receiving prophylaxis for respiratory syncytial virus (RSV) disease by describing the patterns and scope of usage of palivizumab in a cross section of US infants. RSV hospitalization outcomes were also described. The Palivizumab (Synagis®, MedImmune, Inc., 25 West Watkins Mill Road, Gaithersburg, MD 20878) Outcomes Registry was a prospective multicenter survey conducted at 63 sites. Demographics, injection history, and RSV hospitalization outcomes were collected on 2,116 infants receiving palivizumab. Infants were enrolled in the Registry between September 1, 2000–March 1, 2001, at the time of their first injection. Infants born at less than 32 weeks of gestation accounted for 47% of infants enrolled, and those between 32–35 weeks accounted for 45%; approximately 8% were greater than 35 weeks of gestation. Lower RSV hospitalization rates were observed in infants who had greater adherence to regularly scheduled injections. Nearly one‐half of all hospitalizations occurred within the first and second injection intervals, suggesting the importance of early RSV protection. The confirmed RSV hospitalization rate of all infants in the Registry was 2.9%; the rate was 5.8% in infants with chronic lung disease of infancy, and 2.1% in premature infants without chronic lung disease. In conclusion, these data support the continued effectiveness of palivizumab prophylaxis for severe RSV lower respiratory tract disease in a large cohort of high‐risk infants from geographically diverse pediatric offices and clinics. The Palivizumab Outcomes Registry provides an opportunity to assess palivizumab utilization and clinical effectiveness in the US. Pediatr Pulmonol. 2003; 35:484–489. © 2003 Wiley‐Liss, Inc.